23.09
2.53%
0.57
Schlusskurs vom Vortag:
$22.52
Offen:
$22.85
24-Stunden-Volumen:
63,793
Relative Volume:
0.46
Marktkapitalisierung:
$844.55M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+10.21%
1M Leistung:
-8.45%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Firmenname
Rapport Therapeutics Inc
Sektor
Branche
Telefon
857-321-8020
Adresse
1325 BOYLSTON STREET, BOSTON
Vergleichen Sie RAPP mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
RAPP | 23.09 | 844.55M | 0 | 0 | 0 | 0.00 |
VRTX | 450.97 | 116.38B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 738.00 | 82.09B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 605.92 | 36.14B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 113.13 | 27.25B | 3.30B | -501.07M | 1.03B | 11.54 |
Rapport Therapeutics Inc Aktie (RAPP) Neueste Nachrichten
Two new option listings and one option delisting on November 21st - TipRanks
LMR Partners LLP Sells 30,000 Shares of Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
(RAPP) Investment Analysis and Advice - Stock Traders Daily
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.5% – Should You Sell? - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 6.5%Time to Sell? - MarketBeat
Cormorant Asset Management's Strategic Acquisition in Rapport Th - GuruFocus.com
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting - GlobeNewswire
Rapport Therapeutics to Present Phase 2a Epilepsy Drug Data at Major Conference | RAPP Stock News - StockTitan
FMR LLC's Strategic Acquisition in Rapport Therapeutics Inc - GuruFocus.com
Cartesian Therapeutics (NASDAQ:RNAC) & Rapport Therapeutics (NASDAQ:RAPP) Head to Head Comparison - Defense World
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates - MSN
(RAPP) Investment Report - Stock Traders Daily
Rapport Therapeutics Inc (RAPP) Quarterly 10-Q Report - Quartzy
Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update - The Manila Times
Rapport (RAPP) Hit With FDA Hold Despite $320M Cash Position; Q3 Loss Widens | RAPP Stock News - StockTitan
Rapport Therapeutics to Present at Stifel Healthcare - GlobeNewswire
Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November - StockTitan
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up – Still a Buy? - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap UpHere's Why - MarketBeat
SG Americas Securities LLC Makes New Investment in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
(RAPP) Trading Report - Stock Traders Daily
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 4.2%Here's Why - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap DownShould You Sell? - MarketBeat
Jones Trading Initiates Coverage of Rapport Therapeutics (RAPP) with Buy Recommendation - MSN
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 2.7%Time to Sell? - MarketBeat
This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - MSN
When (RAPP) Moves Investors should Listen - Stock Traders Daily
Rapport Therapeutics (NASDAQ:RAPP) Sets New 1-Year HighTime to Buy? - MarketBeat
Millennium Management LLC Makes New $2.72 Million Investment in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Short Interest Up 32.4% in September - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.3%What's Next? - MarketBeat
75,516 Shares in Rapport Therapeutics (NASDAQ:RAPP) Purchased by The Manufacturers Life Insurance Company - MarketBeat
Two more Mass. biotechs raise $330M in IPOs, to debut on Nasdaq - The Business Journals
(RAPP) On The My Stocks Page - Stock Traders Daily
Rapport Therapeutics (NASDAQ:RAPP) Trading Up 7%Should You Buy? - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 4.1% - MarketBeat
Logos Global Management LP Makes New Investment in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Perceptive Advisors LLC Acquires New Position in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Trading 6.2% Higher - MarketBeat
GC Therapeutics: $65 Million (Series A) Raised To Unlock The Next Generation Of Cell Therapy-Based Medicines - Pulse 2.0
(RAPP) Technical Data - Stock Traders Daily
ARCH Venture Management LLC Makes New $86.73 Million Investment in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
ARCH Venture Management LLC Invests $86.73 Million in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
GC Therapeutics Raises $65M Series A - citybiz
Biogen, Alnylam-partnered Camp4 Therapeutics unveils IPO plans - The Business Journals
Rapport Therapeutics Inc. (RAPP) rating initates by TD Cowen - Knox Daily
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 2.4% - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 4.7% - Defense World
GC Therapeutics Announces Launch Scale and Unlock the Next Generation of Cell Therapy - citybiz
Reckitt shares up on report of potential homecare asset sale By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals initiated with a Buy at H.C. Wainwright - TipRanks
Finanzdaten der Rapport Therapeutics Inc-Aktie (RAPP)
Es liegen keine Finanzdaten für Rapport Therapeutics Inc (RAPP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):